Dazhong Stomatology (2651.HK) IPO Analysis: Growth Opportunities and Challenges for the Leading Stomatology Company in Central China

1. Company Overview: Leading Private Dental Healthcare Provider in Central China, Chain Model Builds Barriers

Wuhan Dazhong Oral Healthcare Co., Ltd. is a private dental healthcare service provider in Central China, primarily operating in Hubei and Hunan. As of the latest practicable date, it operates 92 dental institutions (4 hospitals, 80 clinics, and 8 dental offices), ranking first in the Central China private dental market with a 2.4% market share in 2024. The company adopts a "direct chain + partner plan" model, deepening community healthcare under the unified brand "Aishang Dazhong Oral." From 2022 to 2024, patient visits were 708,700, 768,800, and 748,600, respectively, with a dentist retention rate exceeding 87%. Core services include general dentistry (53.4% of revenue), dental implants (28.4%), and orthodontics (18.2%).

2. Financial Performance: Stable Profitability Under Short-Term Challenges, Cost Control Stands Out

1. Revenue and Profit: Strong Anti-Cyclical Capability

Revenue Scale: From 2022 to 2024, revenues were RMB 409 million, RMB 442 million, and RMB 407 million, respectively. In 2024, due to slow post-pandemic consumption recovery and centralized procurement policies, revenue fell by 7.9% year-on-year. However, net profit remained at RMB 62.5 million (net margin of 15.4%), with gross margin stable at around 37.4%, demonstrating strong cost control (sales costs accounted for ~60%, dentist costs ~23% of sales costs).

Cash Flow: Net operating cash flow remained stable at RMB 100-150 million. In 2024, due to dividends and financing activities, the year-end cash balance was RMB 95.046 million, indicating short-term liquidity pressure.

2. Core Drivers: Structural Growth in Implant and Orthodontic Services

Dental implant visits increased from 59,800 in 2022 to 86,800 in 2024, but due to centralized procurement, the average price dropped from RMB 1,953 to RMB 1,332, with revenue share remaining at ~28%. Orthodontic visits grew to 145,300, with the average price falling to RMB 510, accounting for 18.2% of revenue. General dentistry, as the foundational business, contributed over 50% of revenue, serving as a cash flow stabilizer.

3. Industry Outlook: Private Dental Sector's Golden Era, Central China's Potential Stands Out

1. Market Size: Trillion-Yuan Market Continues to Expand

China's dental healthcare market reached RMB 147.2 billion in 2024 and is projected to grow to RMB 200.4 billion by 2029 (CAGR: 6.4%), with private players accounting for over 70% (2024-2029 CAGR: 7%). Central China's private dental market was RMB 17.4 billion in 2024, expected to reach RMB 25.3 billion by 2029 (CAGR: 7.8%). Hubei and Hunan are densely populated (~110 million in 2024), but the number of dentists per million people is only 197, below the national average, indicating a supply gap.

2. Policy and Competition: Centralized Procurement Drives Efficiency, Chain Expansion is the Trend

Policy-wise, since 2023, centralized procurement for dental implants has been implemented, with Hubei and Hunan requiring private institutions to price reasonably. The company proactively reduced prices by 25%-40% in 2023 but maintained stable gross margins through supply chain optimization (top 5 suppliers accounted for 42.4% of procurement) and economies of scale.

The competitive landscape is highly fragmented, with the top 5 private dental players holding less than 5% market share in 2024. Dazhong Oral leads Central China with 702 dental chairs, leveraging standardized services and brand recognition under its direct-chain model.

4. IPO Details and Valuation: Reasonable Valuation but Liquidity Concerns

1. IPO Overview

Global offering of 10.8618 million H shares (Hong Kong offering: 1.0862 million, international offering: 9.7756 million), priced at HKD 20-21.4, implying a market cap of HKD 988 million-1.057 billion. Net proceeds are ~HKD 186 million, primarily for new institutions (35%), acquisitions (25%), and IT upgrades.

Sponsor: Haitong International, with average historical performance.

Greenshoe: Yes

Clawback: Up to 50%

Cornerstone Investors: None

2. Valuation Comparison

Based on 2024 net profit of RMB 62.5 million (~HKD 68.4 million), the P/E is ~16x, lower than A-share leader Tongcheng Yiliao (~36x dynamic P/E), offering a margin of safety.

5. Risk Warnings: Three Key Challenges

1. Policy Risk: Centralized procurement may expand to orthodontics, further pressuring service prices;

2. Expansion Risk: Plans to open 80-100 new institutions in 5 years may drag short-term profits due to ramp-up periods;

3. Talent Risk: Intense competition for dentists; if the partner plan fails to retain core teams, service quality may suffer.

6. IPO Strategy: Long-Term Value Over Short-Term Speculation

1. Target Investors

Recommendation: Suitable for risk-tolerant investors. This IPO has the smallest fundraising size among six recent listings, with no cornerstone investors, there's room for clawback-driven speculation. If clawback occurs, retail allocation rates may be low.

2. Conclusion

Dazhong Oral, as Central China's private dental leader, benefits from "regional focus + chain expansion + talent retention." Despite short-term policy and consumption headwinds, long-term growth prospects are clear, and valuations are reasonable. Risk-tolerant investors may participate but should manage positions based on market sentiment.

Risk Disclosure: First-day performance is subject to macro and market sentiment. This analysis is not investment advice; investors should make independent decisions.$Dazhong Dental(02651.HK)